Navigation Links
InterMune Announces Presentations of New Research in IPF at ERS
Date:8/27/2012

is currently in a Phase 3 clinical trial to support regulatory registration in the United States.  Additional information about the study is available at www.ASCENDtrial.com.  InterMune's research programs are focused on the discovery of targeted, small-molecule therapeutics and biomarkers to treat and monitor serious pulmonary and fibrotic diseases.  For additional information about InterMune and its R&D pipeline, please visit www.intermune.com.

Forward-Looking Statements
This news release contains forward-looking statements within the meaning of section 21E of the Securities Exchange Act of 1934, as amended, that reflect InterMune's judgment and involve risks and uncertainties as of the date of this release.  All forward-looking statements and other information included in this press release are based on information available to InterMune as of the date hereof, and InterMune assumes no obligation to update any such forward-looking statements or information. InterMune's actual results could differ materially from those described in InterMune's forward-looking statements.

Other factors that could cause or contribute to such differences include, but are not limited to, those discussed in detail under the heading "Risk Factors" in InterMune's most recent annual report on Form 10-K filed with the Securities and Exchange Commission (SEC) on February 29, 2012 (the "Form 10-K"), most recent quarterly report on Form 10-Q filed with the SEC on August 8, 2012 (the "Form 10-Q") and other periodic reports filed with the SEC, including but not limited to the following: (i) the risks related to the uncertain, lengthy and expensive clinical development process for the company's product candidates, including having no unexpected safety, toxicology, clinical or other issues and having no unexpected clinical trial results such as unexpected new clinical d
'/>"/>

SOURCE InterMune, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. InterMune to Divest Actimmune® (Interferon Gamma-1b)
2. InterMune Reports Second Quarter 2012 Financial Results and Business Highlights
3. Precision Optics Corporation Announces $1 Million Order for Microprecision™ Based Endoscopes
4. Young Innovations, Inc. Announces Record Sales and EPS for the Quarter Ended March 31, 2012
5. JDRF Announces Research Collaboration with Dexcom, Inc. to Develop "Smart Transmitter" Technology to Accelerate Artificial Pancreas Studies
6. Misonix Announces New Distribution Agreement For Panama
7. University of Maryland BioPark Announces MedImmunes Dr. Bahija Jallal as Newest Member of Board of Directors for UM Health Sciences Research Park
8. Novelos Therapeutics Announces Successful Completion of First Cohort In Lung Cancer Trial With I-124-CLR1404 (LIGHT) Cancer-Targeted PET Imaging Agent at UW Carbone Cancer Center
9. Boston Scientific Announces CE Mark and European Launch of Emerge™ PTCA Dilatation Catheter
10. Soligenix Announces Further Progress with ThermoVax™ for Long-Term Vaccine ThermoStability
11. Masimo Announces New Low-Profile Infant and Neonatal Pulse Oximetry Sensors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2015)... , May 4, 2015 Unchained Labs, ... out to this year,s PEGS conference and launches the ... system for biologics. PEGS: The Essential Protein Engineering Summit ... 4-8, 2015. The UNit lets drug discovery ... other tool out there. Its 7 applications, 144 sample ...
(Date:5/4/2015)... , May 4, 2015 ... of Michael Williams into the newly ... Williams is a senior pharmaceutical executive with world-class ... also long and distinguished service at industry leaders ... expertise spans a broad range of therapeutic areas, ...
(Date:5/4/2015)... 4, 2015 CytoSorbents Corporation (NASDAQ CM: ... CytoSorb® extracorporeal cytokine adsorber to treat critically-ill and ... report Q1 2015 financial results after the market ... CytoSorbents, management will host a live conference ... operational and financial progress during Q1 2015 followed ...
Breaking Medicine Technology:Unchained Labs Lets the UNit Loose 2Intarcia Names Top Commercial Expert Michael Williams As COO; Will Chair Commercial Committee And Lead ITCA 650 Launch In U.S. 2Intarcia Names Top Commercial Expert Michael Williams As COO; Will Chair Commercial Committee And Lead ITCA 650 Launch In U.S. 3Intarcia Names Top Commercial Expert Michael Williams As COO; Will Chair Commercial Committee And Lead ITCA 650 Launch In U.S. 4CytoSorbents to Report Q1 2015 Operating and Financial Results 2CytoSorbents to Report Q1 2015 Operating and Financial Results 3
... Inc. (OTCPK: ILNS) announces that Dr. Daniel G. ... the 10TH Annual BIO Investor Forum.  Hosted by ... seeking capital, distribution, and visibility with investors and ... healthcare companies. The meeting will take place January ...
... Calif., Dec. 14, 2011  AtheroNova Inc. (OTCBB: AHRO) ... and development of compounds to regress atherosclerotic plaque ... I and Phase II protocol outlines, based on ... New Drug) meeting with the U.S. Food and ...
Cached Medicine Technology:Intellect Neurosciences, Inc. to Present at OneMedForum 2Intellect Neurosciences, Inc. to Present at OneMedForum 3FDA Agrees With AtheroNova's Clinical Development Plan as Proposed 2FDA Agrees With AtheroNova's Clinical Development Plan as Proposed 3
(Date:5/4/2015)... 2015 CCL, a top-ranked, global provider ... program to other leadership development consultancies. “The CCL ... and successful practitioners, expanding our capacity to drive results ... John R. Ryan, CCL President and CEO. , As ... Partner Network , it will schedule a one-on-one conference ...
(Date:5/4/2015)... May 04, 2015 San Diego ... ceremony at their brand new, 13,700 square foot facility ... new building will not only provide fertility treatment and ... also offer community and educational events to a number ... is located next door to their current Carmel Valley/Del ...
(Date:5/4/2015)... Dr. Benjamin Stong of Kalos Facial ... latest non-surgical double-chin eliminator. Dr. Stong is double ... Atlanta to offer Kybella treatments . The FDA ... under the chin, promising to safely dissolve fat deposits ... who sought immediate solutions for their double chin were ...
(Date:5/4/2015)... 04, 2015 Unlike some camps, the Nike Middle ... The goal is to educate first and train second, with ... ensures that the young runners are building the knowledge base needed ... of the topics covered include Effort Based Training, Running Heroes, Running ... to be? This is not a camp where kids come ...
(Date:5/4/2015)... (PRWEB) May 04, 2015 Dr. Richard ... has been chosen to receive the America’s Best Dentist ... Dr. Champagne’s selection as a top dentist is a ... to continuing education and his compassion for his patients. ... professionals who exemplify excellence in their field. These nominees ...
Breaking Medicine News(10 mins):Health News:The Center for Creative Leadership Is Partnering with Lead Star to Create the CCL Partner Network 2Health News:San Diego Fertility Center Hosted a Ribbon Cutting Ceremony at Its New, Expanded Facility 2Health News:San Diego Fertility Center Hosted a Ribbon Cutting Ceremony at Its New, Expanded Facility 3Health News:Facial Plastic Surgeon First in Atlanta To Offer Kybella Treatments To Reduce Chin Fat 2Health News:US Sports Camps and Select Nike Running Camps Offer Programs for Middle School Runners 2Health News:New Jersey Dentist Dr. Richard Champagne Nominated for America’s Best Dentist Award 2
... delivery combination selectively crosses the tight barrier that protects the ... to brain tumors, a research team led by scientists from ... the January issue of the Journal of Clinical Investigation ... the targeted particles guide payloads to image tumors, treat tumors, ...
... (HealthDay News) -- HIV-positive teens and young women are more likely ... who do not have HIV, a new study finds. Researchers ... aged 13 to 24, who had been treated at four hospitals ... some more than once, for a total of 96 pregnancies. ...
... By Serena Gordon HealthDay Reporter , TUESDAY, ... for profit are more likely to have patients who require ... who need longer times in hospice care, research reveals. ... hospices a flat daily rate, regardless of care needs -- ...
... research from University of Michigan says brain scans showing ... the person whose brain is being scanned. Emily ... recently led a study that scanned the brain activity ... would have an impact on their ability to quit ...
... from human placenta left over from live births and ... one kind of melatonin receptor, MT1. This potentially therapeutic ... laboratory test tube and animal models of stroke. ... with melatonin receptor MT2. Researchers from the University ...
... HealthDay Reporter , TUESDAY, Feb. 1 (HealthDay News) ... from meningococcal meningitis, a potentially deadly infection of the ... up-to-date whooping cough vaccines in light of recent outbreaks, ... American Academy of Pediatrics issues updated vaccination guidelines annually. ...
Cached Medicine News:Health News:Targeted particle fools brain's guardian to reach tumors 2Health News:Targeted particle fools brain's guardian to reach tumors 3Health News:Targeted particle fools brain's guardian to reach tumors 4Health News:HIV Linked to Higher Pregnancy Rate in Young Women 2Health News:For-Profit Hospices May Prefer Certain Types of Patients: Study 2Health News:For-Profit Hospices May Prefer Certain Types of Patients: Study 3Health News:Brain scans predict likely success when it comes to quitting smoking 2Health News:Transplanted human placenta-derived stem cells show therapeutic potential in stroke models 2Health News:Pediatricians Issue New Vaccination Recommendations 2Health News:Pediatricians Issue New Vaccination Recommendations 3
4 hour identification of over 70 medically important, oxidase-negative, gram-negative bacilli, including E. coli, based on enzyme technology....
Agglutinating sera for serological identification of E. coli by slide and/or tube agglutination tests. Agglutinating sera are packaged 2 mL / vial....
For presumptive identification of Escherichia coli using enzyme technology. Tests: Indole, MUG...
A direct qualitative enzyme immunoassay for detection of E.coli Shiga Toxin 1 and 2 in fresh or preserved fecal specimens....
Medicine Products: